# Xerient Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xerient-pharma

- Industry: Pharmaceuticals
- Headquarters: Houston, US
- Website: https://xerient.net/
- Latest round: Seed (Jul 1, 2023)
- Investors on record: 1

## About

Based in Houston, the US, and founded by Guy Yachin and Michael Shtein in 2019, Xerient Pharma Ltd. operates as a pharmaceutical manufacturer specifically targeting abdominal and gastrointestinal cancers, with an emphasis on pancreatic cancer. Xerient Pharma Ltd. raised venture funding from investor Peregrine Ventures.

The company is developing a portfolio of products to improve survival rates for hard-to-treat cancers using radioprotective therapeutics that allow the use of radiotherapy for pancreatic cancer by protecting surrounding sensitive tissues. Xerient's strategy involves repurposing an FDA-approved drug for novel cancer treatments, ensuring safety, and complementing existing therapies. Their efforts aim to make significant advances in early detection and effective treatment of pancreatic cancer and other related cancers.

## Funding rounds

- Seed, Jul 1, 2023 — Peregrine Ventures

## Investors

- Peregrine Ventures (https://capitalatlas.ai/funds/peregrine-ventures) — Seed